HC Wainwright Issues Pessimistic Forecast for CRDF Earnings

Cardiff Oncology, Inc. (NASDAQ:CRDF) – Stock analysts at HC Wainwright dropped their Q2 2026 earnings per share estimates for Cardiff Oncology in a research note issued on Friday, May 15th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.13) per share for the quarter, down from their prior estimate of ($0.11). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Cardiff Oncology’s current full-year earnings is ($0.60) per share. HC Wainwright also issued estimates for Cardiff Oncology’s Q3 2026 earnings at ($0.13) EPS, Q4 2026 earnings at ($0.13) EPS and FY2026 earnings at ($0.56) EPS.

A number of other analysts have also issued reports on the company. Piper Sandler dropped their target price on Cardiff Oncology from $10.00 to $6.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 25th. Wall Street Zen lowered Cardiff Oncology from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cardiff Oncology in a research report on Wednesday, January 21st. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Cardiff Oncology has a consensus rating of “Moderate Buy” and a consensus price target of $10.10.

Cardiff Oncology Stock Performance

Shares of NASDAQ CRDF opened at $1.69 on Tuesday. Cardiff Oncology has a 1 year low of $1.48 and a 1 year high of $4.56. The firm has a market cap of $115.55 million, a price-to-earnings ratio of -2.52 and a beta of 1.36. The stock’s 50-day simple moving average is $1.71 and its 200-day simple moving average is $2.08.

Cardiff Oncology (NASDAQ:CRDF) last announced its earnings results on Thursday, May 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05). Cardiff Oncology had a negative return on equity of 95.51% and a negative net margin of 8,527.43%.The business had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.09 million.

Institutional Trading of Cardiff Oncology

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC bought a new stake in Cardiff Oncology in the first quarter valued at about $164,000. Sei Investments Co. bought a new stake in Cardiff Oncology in the first quarter valued at about $89,000. Virtu Financial LLC bought a new stake in Cardiff Oncology in the fourth quarter valued at about $108,000. XTX Topco Ltd increased its holdings in Cardiff Oncology by 40.5% in the fourth quarter. XTX Topco Ltd now owns 219,357 shares of the company’s stock valued at $616,000 after buying an additional 63,196 shares during the last quarter. Finally, Millennium Management LLC increased its holdings in Cardiff Oncology by 441.5% in the fourth quarter. Millennium Management LLC now owns 194,420 shares of the company’s stock valued at $546,000 after buying an additional 158,519 shares during the last quarter. 16.29% of the stock is owned by institutional investors.

About Cardiff Oncology

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.